The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.
Aged
Aged, 80 and over
Albumins
/ pharmacology
Animals
Carcinoma, Pancreatic Ductal
/ drug therapy
Drug Resistance, Neoplasm
Female
Gene Expression Regulation, Neoplastic
Humans
Male
Mice
Neoplasm Transplantation
Paclitaxel
/ pharmacology
Pancreatic Neoplasms
/ drug therapy
Primary Cell Culture
Proto-Oncogene Proteins c-myc
/ genetics
Tumor Cells, Cultured
Up-Regulation
Zebrafish
Pancreatic Neoplasms
Journal
Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
15
02
2019
revised:
18
04
2019
accepted:
31
05
2019
pubmed:
6
6
2019
medline:
18
6
2020
entrez:
6
6
2019
Statut:
ppublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and, very often, ineffective medical and surgical therapeutic options. The treatment of patients with advanced unresectable PDAC is restricted to systemic chemotherapy, a therapeutic intervention to which most eventually develop resistance. Recently, nab-paclitaxel (n-PTX) has been added to the arsenal of first-line therapies, and the combination of gemcitabine and n-PTX has modestly prolonged median overall survival. However, patients almost invariably succumb to the disease, and little is known about the mechanisms underlying n-PTX resistance. Using the conditionally reprogrammed (CR) cell approach, we established and verified continuously growing cell cultures from treatment-naïve patients with PDAC. To study the mechanisms of primary drug resistance, nab-paclitaxel-resistant (n-PTX-R) cells were generated from primary cultures and drug resistance was verified
Identifiants
pubmed: 31164413
pii: 1541-7786.MCR-19-0191
doi: 10.1158/1541-7786.MCR-19-0191
pmc: PMC6726538
mid: NIHMS1531263
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
MYC protein, human
0
Proto-Oncogene Proteins c-myc
0
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1815-1827Subventions
Organisme : NIMHD NIH HHS
ID : R01 MD012767
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001432
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA051008
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009686
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA240993
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA194730
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA056036
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Mol Cancer Res. 2014 Jun;12(6):924-39
pubmed: 24667985
Oncotarget. 2017 Jul 25;8(30):48534-48544
pubmed: 28159918
Cell Metab. 2015 Oct 6;22(4):590-605
pubmed: 26365176
Science. 2014 Dec 19;346(6216):1480-6
pubmed: 25394791
Oncotarget. 2014 Nov 15;5(21):10678-91
pubmed: 25296977
Eur J Cancer. 2014 Aug;50(12):2072-81
pubmed: 24915778
Methods Mol Biol. 2017;1606:149-169
pubmed: 28502000
J Clin Invest. 2017 Jun 1;127(6):2081-2090
pubmed: 28504649
Nat Methods. 2013 Dec;10(12):1169-76
pubmed: 24296474
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Eur J Cancer. 2011 Nov;47(17):2654-64
pubmed: 21958460
Nat Commun. 2016 Mar 18;7:11046
pubmed: 26988139
Oncotarget. 2017 Dec 25;9(4):5274-5286
pubmed: 29435178
Cancer Res. 2016 Apr 15;76(8):2243-2253
pubmed: 26893480
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Sci Transl Med. 2018 Jul 18;10(450):
pubmed: 30021885
Sci Rep. 2017 Apr 05;7:45617
pubmed: 28378747
Nat Protoc. 2017 Feb;12(2):439-451
pubmed: 28125105
J Biomed Sci. 2018 Sep 4;25(1):67
pubmed: 30176860
N Engl J Med. 2012 Sep 27;367(13):1220-7
pubmed: 23013073
Mol Oncol. 2015 Apr;9(4):889-905
pubmed: 25637283
Cell Mol Life Sci. 2018 Aug;75(15):2695-2718
pubmed: 29725697
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Oncotarget. 2014 Mar 30;5(6):1683-98
pubmed: 24742967
Cell. 2015 Jan 15;160(1-2):324-38
pubmed: 25557080
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Prostate. 2006 May 15;66(7):708-17
pubmed: 16425198
Nature. 2016 Dec 8;540(7632):292-295
pubmed: 27919066
EMBO Mol Med. 2017 Feb;9(2):181-197
pubmed: 28003334
Oncotarget. 2018 Feb 13;9(19):14764-14790
pubmed: 29599906
Trends Cell Biol. 2015 Apr;25(4):241-8
pubmed: 25475704
Am J Pathol. 2012 Feb;180(2):599-607
pubmed: 22189618
Oncotarget. 2017 Dec 18;9(2):2193-2207
pubmed: 29416764
BMC Cancer. 2019 Jan 8;19(1):40
pubmed: 30621618
Oncotarget. 2017 Apr 4;8(14):22741-22758
pubmed: 28009986
Oncogene. 2018 May;37(21):2757-2772
pubmed: 29511349
Cancer Cell. 2018 Nov 12;34(5):807-822.e7
pubmed: 30423298
Cancer Res. 2019 Jan 1;79(1):209-219
pubmed: 30389701
Am J Pathol. 2013 Dec;183(6):1862-1870
pubmed: 24096078
Clin Cancer Res. 2017 Apr 1;23(7):1647-1655
pubmed: 28373363
Hum Mutat. 2016 Mar;37(3):235-41
pubmed: 26555599
Curr Protoc Bioinformatics. 2013;43:11.10.1-11.10.33
pubmed: 25431634
IEEE/ACM Trans Comput Biol Bioinform. 2014 Nov-Dec;11(6):1009-19
pubmed: 25750594
Nature. 2018 Aug;560(7717):156-157
pubmed: 30087485
Nature. 2018 Aug;560(7718):325-330
pubmed: 30089904
Genes Dev. 2000 Oct 1;14(19):2501-14
pubmed: 11018017
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Nat Med. 2015 Nov;21(11):1364-71
pubmed: 26501191
Sci Rep. 2018 Mar 6;8(1):4097
pubmed: 29511269